For never-smokers with HER2 mutations, immunotherapy is largely ineffective and risks severe immune-related adverse events when the patient is later switched to the correct TKI. This paradigm mirrors the approach for EGFR and ALK mutations, where targeted therapy is the standard upfront, even with high PD-L1 expression.

The CheckMate 9LA regimen provides exceptional benefit to PD-L1 negative and squamous histology NSCLC patients. This is significant because these subgroups often respond poorly to other immunotherapy combinations, with Dr. Carbone noting some trials where the control arm outperformed pembrolizumab in these patients.

Despite the success of perioperative chemo-immunotherapy, it is contraindicated for patients with resectable NSCLC harboring EGFR or ALK driver mutations. These molecular markers predict limited benefit from immune checkpoint inhibitors (ICIs), and NCCN guidelines explicitly recommend against using ICI in this population in favor of targeted therapies.

When a lung cancer patient is too symptomatic to wait for genomic testing results, the expert consensus is to initiate treatment with chemotherapy alone. Adding immunotherapy upfront is ill-advised, as its use in EGFR-mutated patients (a common finding) can be detrimental.

The failure of the concurrent chemo-immuno-radiation approach has not stalled progress. Instead, new clinical trials are actively exploring novel strategies like SBRT boosts, dual checkpoint inhibitors, radiosensitizing nanoparticles, and induction immunotherapy to improve upon the current standard of care.

In PD-L1 negative KRAS-mutated lung cancer, where standard immunotherapy is less effective, adding a CTLA-4 inhibitor can recover the immune response and create long-term survivors. This makes a triplet or quadruplet regimen the current optimal strategy for this challenging patient subgroup.

Standard DNA-based Next-Generation Sequencing (NGS) can miss critical gene fusions, like ROS1. RNA sequencing is much more effective at identifying these specific alterations, so clinicians should ensure their chosen assay includes RNA analysis to avoid missing opportunities for targeted therapy.

Despite major advances in immunotherapy, patient selection remains crude compared to targeted therapies. PD-L1 is still the primary, yet imperfect, biomarker used. Dr. Carbone highlights an urgent need to develop better predictive biomarkers to customize immunotherapy regimens, as is standard for targeted agents.

The list of oncogenic drivers where single-agent immunotherapy is ineffective should be expanded beyond EGFR and ALK to include HER2 mutations. Citing a study where the response rate to immunotherapy was zero percent for these patients, experts advise against using it in this specific molecular subtype.